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Region Västra Götaland, Gothenburg, Sweden, 7 Department of Genetics and Bioinformatics, Division of




Treatment of cervical intraepithelial neoplasia (CIN) is associated with an increased risk of
preterm delivery (PTD) although the exact pathomechanism is not yet understood. Women
with untreated CIN also seem to have an increased risk of PTD. It is unclear whether this is
attributable to human papillomavirus (HPV) infection or other factors. We aimed to investi-
gate whether HPV infection shortly before or during pregnancyAU : Hereandelsewhere; IchangedHPVinconjunctionwithpregnancytoHPVshortlybeforeorduringpregnancy:Ifthiseditdoesnotcaptureyourmeaning; pleaseeditasnecessarythroughout:, as well as pr vious treat-
ment for CIN, is associated with an increased risk of PTD and other adverse obstetric and
neonatal outcomes.
Methods and findings
This was a retrospective population-based register study of women with singleton deliveries
registered in the Swedish Medical Birth Register 1999–2016 (n = 1,044,023). The study pop-
ulation had a mean age of 30.2 years (SD 5.2) and a mean body mass index of 25.4 kg/m2
(SD 3.0), and 44% of the women were nulliparous before delivery. Study groups were
defined based on cervical HPV tests, cytology, and histology, as registered in the Swedish
National Cervical Screening Registry. Women with a history of exclusively normal cytology
(n = 338,109) were compared to women with positive HPV tests (n = 2,550) or abnormal
cytology (n = 11,727) within 6 months prior to conception or during the pregnancy, women
treated for CIN3 before delivery (n = 23,185), and women with CIN2+ diagnosed after deliv-
ery (n = 33,760). Study groups were compared concerning obstetric and neonatal outcomes
by logistic regression, and comparisons were adjusted for socioeconomic and health-related
confounders. HPV infection was associated with PTD (adjusted odds ratio [aOR] 1.19, 95%
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CI 1.01–1.42, p = 0.042), preterm prelabor rupture of membranes (pPROM) (aOR 1.52,
95% CI 1.18–1.96, p < 0.001), prelabor rupture of membranes (PROM) (aOR 1.24, 95% CI
1.08–1.42, p = 0.002), and neonatal mortality (aOR 2.69, 95% CI 1.25–5.78, p = 0.011).
Treatment for CIN was associated with PTD (aOR 1.85, 95% CI 1.76–1.95, p < 0.001),
spontaneous PTD (aOR 2.06, 95% CI 1.95–2.17, p < 0.001), pPROM (aOR 2.36, 95% CI
2.19–2.54, p < 0.001), PROM (aOR 1.11, 95% CI 1.05–1.17, p < 0.001), intrauterine fetal
death (aOR 1.35, 95% CI 1.05–1.72, p = 0.019), chorioamnionitis (aOR 2.75, 95% CI 2.33–
3.23, p < 0.001), intrapartum fever (aOR 1.24, 95% CI 1.07–1.44, p = 0.003), neonatal sep-
sis (aOR 1.55, 95% CI 1.37–1.75, p < 0.001), and neonatal mortality (aOR 1.79, 95% CI
1.30–2.45, p < 0.001). Women with CIN2+ diagnosed within 3 years after delivery had
increased PTD risk (aOR 1.18, 95% CI 1.10–1.27, p < 0.001). Limitations of the study
include the retrospective design and the fact that because HPV test results only became
available in 2007, abnormal cytology was used as a proxy for HPV infection.
Conclusions
In this study, we found that HPV infection shortly before or during pregnancy was associated
with PTD, pPROM, PROM, and neonatal mortality. Previous treatment for CIN was associ-
ated with even greater risks for PTD and pPROM and was also associated with PROM, neo-
natal mortality, and maternal and neonatal infectious complications.
Author summary
Why was this study done?
• Treatment of cervical intraepithelial neoplasia (CIN) is associated with an increased risk
of preterm delivery (PTD), preterm prelabor rupture of the membranes (pPROM), and
neonatal mortality. However, the exact biological mechanism is still unknown.
• Women with untreated CIN also seem to have an increased risk of PTD. It is unknown
whether HPV infection can cause PTD or other adverse obstetric outcomes.
• Although ascending bacterial infection is an established leading cause of PTD, there is
limited knowledge concerning whether PTD after excisional treatment for CIN is asso-
ciated with infectious complications.
What did the researchers do and find?
• This retrospective population-based register study (1999–2016) found that HPV infec-
tion shortly before or during pregnancy is associated with an increased risk of PTD,
pPROM, prelabor rupture of the membranes, and neonatal mortality.
• Treatment for CIN was also associated with these adverse outcomes and with an even
higher risk for PTD and pPROM.
• This study presents new evidence that previous treatment for CIN is associated with an
increased risk of maternal and neonatal infectious complications.
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What do these findings mean?
• Although we cannot claim causality due to the register-based study design, our results
suggest that pregnancies after treatment for CIN should be regarded as high-risk preg-
nancies and counseled accordingly.
• These results support the idea that strategies to mitigate HPV infection, such as vaccina-
tion programs, may be beneficial for maternal and neonatal pregnancy outcomes.
Introduction
Human papillomavirus (HPV) infection is the most common genital infection in women of
reproductive age. Persistent genital infection with high-risk HPV is causally associated with
cervical cancer and its precursor, cervical intraepithelial neoplasia (CIN) [1]. The widespread
introduction of cervical cancer screening [2,3] and subsequent treatment of CIN has lowered
the incidence of cervical cancer significantly [4]. Unfortunately, surgical excision to treat CIN
has been associated with an increased risk of preterm delivery (PTD), preterm prelabor rup-
ture of membranes (pPROM), conditions requiring neonatal intensive care, and neonatal mor-
tality in subsequent pregnancies [5]. PTD, birth before 37 weeks of gestation, is an enormous
global obstetric and societal problem, as it is the main cause of mortality in children under the
age of 5 years, as well as of short- and long-term morbidity [6,7].
The mechanism behind excisional treatment increasing the risk of PTD remains unclear.
The hypotheses include increased risk of ascending bacterial infection, HPV-induced immu-
nomodulation, and acquired “mechanical weakness” secondary to loss of cervical tissue [8].
Although bacterial infection is an established major cause of PTD, especially early PTD and
PTD starting with pPROM [9], there is limited knowledge concerning whether PTD after exci-
sional treatment is associated with infectious complications [10].
The magnitude of the increase in risk for PTD attributed to treatment differs between stud-
ies [8,10–15] and seems to depend on the type of treatment. The risk increase is higher after
excision than after ablation and is highest after cold knife excision [10]. Risk of PTD also
seems to increase with the depth of excision [10]. Furthermore, the risk increase depends on
whether healthy women or women with untreated CIN/HPV infection serve as the compari-
son group [10]. While it has been suggested during recent years that untreated CIN also con-
fers a risk of PTD [8,16,17], a recent Cochrane review and meta-analysis concluded that
further research is needed to understand the causal link and possible pathomechanism [10]. It
is as yet unclear whether the pathomechanism is the HPV infection itself or whether the associ-
ation between CIN and PTD is due to a vulnerability to both conditions, either by genetic pre-
disposition or as a product of confounding [10,16]. It is thus unknown whether HPV infection
can cause PTD or other adverse obstetric outcomes. Studies linking positive HPV tests and/or
abnormal cervical cytology with obstetric outcomes have shown conflicting results [18–21]. A
recent meta-analysis and systematic review suggested an association between HPV infection
and PTD, and possibly pPROM [22], although all included studies were small. Other obstetric
or neonatal outcomes in women with untreated CIN/HPV infection have not been studied in
detail [10,17,23,24].
In summary, the risk of PTD increases after treatment for CIN, but the underlying mecha-
nism is still not known. Women with untreated CIN also seem to have an increased risk of
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PTD, but it has not been established whether this risk is attributable to HPV infection during
pregnancy. Neither the associations between untreated HPV infection in pregnancy and PTD
and other obstetric and neonatal outcomes, nor the association between previous treatment
for CIN and infectious pregnancy complications, have as yet been studied in a comprehensive
population-based study. In this large Swedish national population-based study, we aimed to
investigate whether HPV infection shortly before or during pregnancy is associated with an
increased risk of PTD and other adverse obstetric and neonatal outcomes. We also aimed to
study the association between previous treatment for CIN and PTD and other adverse obstet-
ric and neonatal outcomes, with special focus on infectious complications at birth.
Materials and methods
Data sources
This study is a retrospective population-based study using data from different Swedish health
and population registersAU : Ichangedhealthandqualityregisterstohealthandpopulationregistersbecausequalityregisterisnotidiomatic:Ifthiseditdoesnotcaptureyourmeaning; pleaseeditasnecessary:. Data linka between the registers was performed with the unique
personal identification number held by each resident of Sweden. The Swedish Medical Birth
Register (MBR), established in 1973 and managed by the Swedish National Board of Health
and Welfare, is the object of compulsory registration and thus comprises all live births and
stillbirths in Sweden at 22 completed weeks of gestation and up [25]. The information available
in the register is extracted from antenatal and delivery unit medical records and includes data
on maternal health, reproductive history, pregnancy complications and neonatal outcomes.
The Swedish National Cervical Screening Registry (NKCx) contains data from 1978 onwards,
with full national coverage of all cervical cytology results since 1997 and full national coverage
of histology results since 1998 [26]. Cervical HPV tests have been recorded in the database
since 2007. The Swedish Cancer Register, a mandatory registry established in 1958 and man-
aged by the Swedish National Board of Health and Welfare, registers all diagnosed cancer
cases in Sweden, as well as all cases of CIN3 [27]. Information on education level, country of
birth, and income was obtained from the Swedish Register on Participation in EducationAU : IchangedRegisterofEducationtoRegisteronParticipationinEducation:Thelinkinref 28didnotwork; butIassumeUREGismeant; theEnglishnameofwhich; perStatisticsSweden; isRegisteronParticipationinEducation:Ifthisisnotthecorrectregister; pleaseedit:[28],
the Total Population Register [29], and the Income and Tax Assessment Register [30], man-
aged by Statistics Sweden.
This study is reported as per the Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) guideline (S1 STROBE Checklist). The study was prospectively
planned in 2015, the dataset was received in 2019, and analyses were conducted until Novem-
ber 2020. We did not publish the analysis plan, but the overall exposure, outcomes, confound-
ers, and analyses were planned in 2015 by the research team based on hypotheses drawn from
previous studies. After obtaining and reviewing the content of the dataset, but before starting
the analyses, the final definition of study groups, outcomes, and study period was decided
based on the available data and quality of the dataset. During the analysis process, we decided
to also conduct stratified analyses.
Study population
All women with singleton births between 1 January 1999 and 31 December 2016 were identi-
fied in the MBR. Women with a history of chronic inflammatory disease, human immunodefi-
ciency virus infection, or organ transplantation were excluded (see S1 Table for the
International Classification of DiseasesAU : IchangedInternationalStatisticalClassificationofDiseasetoInternationalClassificationofDiseases:Ifthisisnotcorrect; pleaseedit:[ICD] codes leading to exclusion), leaving a study p p-
ulation comprising 1,787,842 deliveries in 1,044,023 women with a mean age at delivery of
30.2 years (SD 5.2) and a mean body mass index (BMI) of 25.4 kg/m2 (SD 3.0); 44% of the
women were nulliparous before delivery. Of these, 400,583 women had at least 1 delivery that
fulfilled the criteria for inclusion in a study group (see below; Fig 1).
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Exposures
A delivery registered AU : Pleasecheckthattheeditstothesentence}Adelivery:::}captureyourmeaning:Ifnot; pleaseprovidecorrectwording:in the MBR was eligible for inclusion in a study group if the woman ful-
filled the criteria for exposure, i.e., results of a cervical HPV test registered in the NKCx in
2007–2016, cervical cytology or histology registered in the NKCxAU : Shouldcytologyandhistologyði:e:; bothrequiredÞbecytologyorhistology?Ifso; pleasemarkthischange:in 1978–2016, and/or a histo-
logical diagnosis registered in the Swedish Cancer Register. For exact classification of study
groups, see S2 Table. For classification of cytology and histology results, see S3 Table.
A reference group was defined, consisting of women who had a history of exclusively nor-
mal cervical cytology results until the end of the study period and at least 1 sample taken in the
3 years preceding the included delivery (n = 338,109).
The exposure groups were defined as follows:
1. HPV infection group: women with presumed HPV infection during pregnancy, based on
abnormal cervical cytology or positive HPV test recorded within 6 months prior to concep-
tion or during pregnancy. Two partly overlapping subgroups were defined:
1a. HPV infection (cytology): abnormal cytology (n = 11,727).
1b. HPV infection (HPV test): positive cervical HPV test (n = 2,550).
2. Subsequent CIN2+ group: at presumed risk of persistent HPV infection based on a histo-
logical diagnosis of CIN2 or CIN3, adenocarcinoma in situ (AIS), or cervical cancer any
time after delivery (n = 33,760).
3. Treated group: histologically diagnosed CIN3 before conception. Since there is no national
Swedish register covering treatment for CIN, CIN3 was used as a proxy for treatment as
these women are always treated in Sweden, a policy that has been consistent over the study
period (n = 23,185).
In order to avoid women previously treated for CIN being included in the HPV infection
groups or the subsequent CIN2+ group, women with histologically diagnosed CIN1 more
than once or with CIN2+ before the pertinent delivery were excluded from these groups.
Three different treatment periods, based on the year of first diagnosis of CIN3, were
defined, corresponding to differences in predominant mode of treatment: 1978–1985AU : Ichangedbefore1985to1978   1985tomatchTable1; andsothattheyear1985wouldbeincludedintherange:(cold
knife conization), 1986–1995 (tissue-saving methods such as cryotherapy, laser vaporization,
laser conization, and diathermy), and 1996–2016 (large loop excision of the transformation
zone [LLETZ], also referred to as loop electrosurgical excision procedure [LEEP]) [31].
In the treated group, the interval from treatment to delivery was determined, as was the
interval from delivery to CIN2+ diagnosis in the subsequent CIN2+ group.
Outcomes
The primary outcome was PTD at 22–36 weeks of gestation AU : IchangedthetimedefinitionofPTDgivenherefrom22   37weeksto22   36weekstomatchthedefinitiongivenelsewhereinthepaperðbefore37weeksÞandinthetablesð < 37weeksÞ:Ifthisisnotcorrect; pleaseedit:(154–258 days). Gestational age
was retrieved from the MBR using the best estimate, i.e., ultrasound determination when avail-
able and last menstrual period or estimation of gestational age at delivery ward in the remain-
ing cases. Subanalyses for early PTD (22–33 weeks, AU : IchangedthetimedefinitionofearlyPTDgivenherefrom22   34weeksto22   33weekstomatchthedefinitiongiveninthetablesð < 34weeksÞ:Ifthisisnotcorrect; pleaseedit:or 154–237 days, of g station) and for very
early PTD (22–27 weeksAU : IchangedthetimedefinitionofveryearlyPTDgivenherefrom22   28weeksto22   27weekstomatchthedefinitiongiveninthetablesð < 28weeksÞ:Ifthisisnotcorrect; pleaseedit:, or 154–195 days, of gestation) were p rformed.
Secondary outcomes were pPROM (determined according to ICD-10 codes in the MBR)
and spontaneous PTD (defined as pPROM or preterm labor, excluding deliveries that started
with induction or cesarean section, according to ICD-10 codes and MBR parameters).
Further studied outcomes comprised prelabor rupture of membranes (PROM) in term
pregnancies (�37 weeks of gestation)AU : Ichangedtermpregnanciestotermpregnanciesð� 37weeksofgestationÞ:Ifthisaddedparetheticaldefinitionisnotcorrect; pleaseedit:, chorioamnionitis, intrap rtum fever, neonatal s psis,
Apgar score< 7 at 5 minutes, intrauterine fetal death, neonatal mortality (1–28 days), and
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small for gestational age (SGA), defined as birthweight less than −2 SD according to the Swed-
ish reference curves [32] (S4 Table).
Background variables
The following background variables were retrieved from the MBR and from Statistics Sweden
registers: age at delivery, BMI, smoking before and during pregnancy, marital status, education
level at delivery, employment at delivery, disposable household income in the 3 years preceding
deliveryAU : Throughoutthepaper; Ichangeddisposablehouseholdincome3yearsprecedingdeliveryðwhichreadsasapointmeasurement3yearsagoÞtodisposablehouseholdincomeinthe3yearsprecedingdeliveryðameasureencompassingthe3yearsÞbasedonthedefinitionofthevariablegivenlaterintheMethods:Ifthisisnotcorrect; pleaseeditwherevernecessary:, country f birth, parity, infant’s s x, and assisted repr ducti n, as well as chronic renal
disease, diabetes, epilepsy, and chronic hypertension as reported in antenatal care records.
Statistical analyses
Descriptive data are presented as number and percentage for categorical variables and as mean
(SD) and median (interquartile range) AU : Ichangedmedianðinterquartilerange;minimumandmaximumÞtomedianðinterquartilerangeÞbecauseminimumandmaximumarentpresentedinanyofthedatainthemaintext; tables; orfigures:for continuous variables. Analyses were performed
using R (version 4.0.0; R Foundation for Statistical Computing, Vienna, Austria; https://www.
r-project.org/) and SPSS software (version 26.0; IBM; https://www.ibm.com/analytics/spss-
statistics-software). A significance level of 0.05 was applied throughout.
The study groups were compared concerning obstetric and neonatal outcomes by unad-
justed and adjusted logistic regression analysis. If a woman had several deliveries that fulfilled
the criteria for inclusion in a group, only 1 delivery was included. A random delivery in the ref-
erence group was compared to the first eligible delivery after treatment in the treated group
and the last eligible delivery in the HPV infection groups (cytology and HPV test) and the last
delivery before diagnosis of CIN2+ in the subsequent CIN2+ group. The first eligible delivery
after treatment in the treated group was compared to the last delivery in a woman included in
the other exposure groups. This was done to better match for age and parity, since women in
the treated group naturally were older than women in the other exposure groups. Women who
had both a delivery after treatment and a previous delivery included in any of the other expo-
sure groups were excluded from the treated group when the treated group was compared to
the other exposure groups.
HPV infection can exist for a long time before diagnosis of CIN2+. Therefore, the sub-
sequent CIN2+ group was compared to the reference group after stratification for interval
(0–3 years or >3 years) to diagnosis of CIN2+, based on the median interval from delivery to
CIN2+ diagnosis of 3.2 years. The 2 groups were also compared with each other.
Fig 1. Flowchart of the study population. AU : singletonismisspelledinFig1:Pleasefix:CIN, cervical intraepithelial neoplasia; HIV, human immunodeficiency
virus; HPV, human papillomavirus.
https://doi.org/10.1371/journal.pmed.1003641.g001
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Women with a delivery included in the subsequent CIN2+ group followed by a delivery
included in the treated group were included in paired analyses with conditional logistic regres-
sion analysis.
When comparing the HPV infection (HPV test) group with other groups, only deliveries
after 2006 were included, since no HPV tests were registered before that year. In order to test
whether cytology was a valid substitute for a positive HPV test, the 2 HPV infection groups
were compared to each other. In these analyses, women with both a positive HPV test and
abnormal cytology were excluded from the HPV infection (cytology) group.
The multivariable analyses were adjusted for potential confounding factors, including back-
ground variables with an uneven distribution between the groups, i.e., year of delivery (1999–
2001, 2002–2004, 2005–2007, 2008–2010, 2011–2013, 2014–2016), maternal age (<21, 21–25,
26–30, 31–35, 36–40,>40), parity (0, 1, 2, 3,>3), BMI (underweight [<18.5 kg/m2], normal
weight [18.5–24.9 kg/m2], overweight [25.0–29.9 kg/m2], obese�30.0 kg/m2], missing), mari-
tal status (cohabiting, single, other, missing), country of birth (Sweden, Europe, Asia, Amer-
ica/Oceania, Africa, missingAU : Ichangedcountryofbirthother=unknowntomissing:Ifthisisnotcorrect; pleaseedit:), infant’s sex (b y, girl, m ssing), smoki g ( ever, before
pregnancy, in early pregnancy, in the third trimester, missing), highest disposable household
income in the 3 years preceding delivery (population divided into tertiles for every year), edu-
cation level (primary, secondary, post-secondary < 3 years, post-secondary� 3 years, miss-
ing), and assisted reproduction (yes, no). The paired analyses were adjusted for BMI, marital
status, infant’s sex, smoking, and assisted reproduction, with the group definitions defined
above.
In order to study the implication of infectious complications, the treated group was com-
pared with the reference group regarding chorioamnionitis and neonatal sepsis, with adjusted
logistic regression after stratification for PTD. The treated group was also compared with the
reference group regarding chorioamnionitis and neonatal sepsis in PTD cases, after stratifica-
tion for pPROM and also adjusted for gestational age.
Neonatal mortality in the treated and HPV infection groups was compared with that in the
reference group, with adjusted logistic regression analysis also including PTD in the adjust-
ments. Subgroup analysis comparing neonatal mortality in the treated and reference groups
was also performed, after stratification for infectious complications (chorioamnionitis and/or
neonatal sepsis) and also adjusted for gestational age.
In all stratified analyses, differences in odds ratios between strata were analyzed by an inter-
action term between the stratum and the group in logistic regression.
Ethics statement
The study was approved by the Regional Ethical Review Board at the University of Gothenburg
(registration number 614–15). In this retrospective register-based study, no consent was
obtained from the participants since the data were analyzed anonymously.
Results
Characteristics of the study population
Background factors for the study population are presented in Table 1. The study groups dif-
fered, for example regarding age, parity, and smoking. In the reference group, 10% (n = 32,457
women) were older than 35 years, and similarly 10% in the subsequent CIN2+ group (n =
3,492) and 12% in the HPV infection (cytology) group (n = 1,366) were older than 35 years,
while age over 35 years was more frequent in the HPV infection (HPV test) group (n = 429,
17%) and the treated group (n = 4,755, 21%). Nulliparity was most frequent in the treated
group (n = 13,425, 58%) and HPV infection groups (cytology, n = 6,479, 55%; HPV test, n =
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Table 1. Demographics and clinical characteristics in the study groups.
Characteristics Reference group
(n = 338,109)







Age at delivery (years)
<21 858 (0.3) 161 (1.4) 12 (0.5) 10 (0.0) 1,205 (3.6)
21–25 54,778 (16.2) 2,673 (22.8) 445 (17.5) 1,276 (5.5) 7,402 (21.9)
26–30 148,021 (43.8) 4,447 (37.9) 875 (34.3) 7,865 (33.9) 12,099 (35.8)
31–35 101,995 (30.2) 3,080 (26.3) 789 (30.9) 9,279 (40.0) 9,562 (28.3)
36–40 29,344 (8.7) 1,177 (10.0) 368 (14.4) 4,095 (17.7) 3,144 (9.3)
>40 3,113 (0.9) 189 (1.6) 61 (2.4) 660 (2.8) 348 (1.0)
BMI class (kg/m2)
Underweight (<18.5) 6,886 (2.0) 326 (2.8) 79 (3.1) 376 (1.6) 882 (2.6)
Normal weight (18.5–24.9) 193,930 (57.4) 6,871 (58.6) 1,587 (62.2) 13,678 (59.0) 19,233 (57.0)
Overweight (25–29.9) 76,964 (22.8) 2,461 (21.0) 499 (19.6) 5,153 (22.2) 7,348 (21.8)
Obese (�30) 34,493 (10.2) 1,160 (9.9) 253 (9.9) 1,868 (8.1) 2,935 (8.7)
Missing 25,836 (7.6) 909 (7.8) 132 (5.2) 2,110 (9.1) 3,362(10.0)
Smoking
Never 286,236 (84.7) 8,582 (73.2) 2,057 (80.7) 16,735 (72.2) 22,151 (65.6)
Before pregnancy 25,166 (7.4) 1,327 (11.3) 260 (10.2) 2,727 (11.8) 4,415 (13.1)
In early pregnancy 6,254 (1.8) 530 (4.5) 56 (2.2) 1,079 (4.7) 2,102 (6.2)
In the third trimester 9,111 (2.7) 941 (8.0) 121 (4.7) 1,732 (7.5) 3,793 (11.2)
Missing 11,342 (3.4) 347 (3.0) 56 (2.2) 912 (3.9) 1,299 (3.8)
Infant’s sex
Boy 174,095 (51.5) 6,108 (52.1) 1,322 (51.8) 11,853 (51.1) 17,297 (51.2)
Girl 164,000 (48.5) 5,618 (47.9) 1,228 (48.2) 11,331 (48.9) 16,462 (48.8)
Missing 14 1 0 1 1
Assisted reproduction1 9,341 (2.8) 153 (1.3) 46 (1.8) 934 (4.0) 434 (1.3)
Employment
Full-time 181,520 (53.7) 5,728 (48.8) 1,458 (57.2) 14,315 (61.7) 14,719 (43.6)
Part-time 79,475 (23.5) 2,469 (21.1) 438 (17.2) 4,278 (18.5) 8,390 (24.9)
None 47,200 (14.0) 2,388 (20.4) 449 (17.6) 2,359 (10.2) 6,605 (19.6)
Missing 29,914 (8.8) 1,142 (9.7) 205 (8.0) 2,233 (9.6) 4,046 (12.0)
Parity
0 163,533 (48.4) 6,479 (55.2) 1,481 (58.1) 13,425 (57.9) 12,730 (37.7)
1 129,737 (38.4) 3,407 (29.1) 724 (28.4) 5,968 (25.7) 14,547 (43.1)
2 36,004 (10.6) 1,308 (11.2) 257 (10.1) 2,788 (12.0) 4,826 (14.3)
3 6,780 (2.0) 354 (3.0) 54 (2.1) 751 (3.2) 1,187 (3.5)
>3 2,055 (0.6) 179 (1.5) 34 (1.3) 253 (1.1) 470 (1.4)
Marital status
Cohabiting 312,277 (92.4) 10,286 (87.7) 2,252 (88.3) 20,777 (89.6) 29,551 (87.5)
Single 3,625 (1.1) 346 (3.0) 63 (2.5) 443 (1.9) 1,007 (3.0)
Other 7,369 (2.2) 626 (5.3) 126 (4.9) 792 (3.4) 1,605 (4.8)
Missing 14,838 (4.4) 469 (4.0) 109 (4.3) 1,173 (5.1) 1,597 (4.7)
Concurrent disease2AU : InTable1; IchangedIntercurrentdiseasetoConcurrentdiseasebecauseintercurrentdiseasemeansadiseasethatemergesorintervenesduringanotherdiseaseðinthiscase; thepregnancyÞ;whichdoesntseemtofitchronicrenaldiseaseðasgiveninthemaintextÞandchronichypertension:Ifthisisnotcorrect;pleaseedit:OthertermsthatmightcaptureyourmeanignarePreviousdiagnosesorComorbidities:
Renal disease 1,326 (0.4) 63 (0.5) 17 (0.7) 110 (0.5) 184 (0.5)
Diabetes 1,864 (0.6) 69 (0.6) 14 (0.5) 104 (0.4) 144 (0.4)
Epilepsy 1,519 (0.4) 66 (0.6) 15 (0.6) 121 (0.5) 176 (0.5)
Chronic hypertension 1,218 (0.4) 39 (0.3) 12 (0.5) 99 (0.4) 108 (0.3)
Education level3
Primary school, up to 9 years 20,947 (6.2) 1,439 (12.3) 234 (9.2) 1,798 (7.8) 4,820 (14.3)
Secondary 136,656 (40.4) 5,329 (45.54) 967 (37.9) 10,092 (43.5) 17,386 (51.5)
(Continued)
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Post-secondary < 3 years 46,648 (13.8) 1,525 (13.0) 358 (14.0) 3,438 (14.8) 4,007 (11.9)
Post-secondary� 3 years 132,012 (39.0) 3,294 (28.1) 971 (38.1) 7,806 (33.7) 7,148 (21.2)
Missing 1,846 (0.5) 140 (1.2) 20 (0.8) 51 (0.2) 399 (1.2)
Country of birthAU : InTable1; Ichangedcountryofbirthunknown=missingtomissing:Ifthisisnotcorrect;pleaseedit:
Sweden 290,269 (85.9) 9,597 (81.8) 2,053 (80.5) 21,395 (92.3) 29,724 (88.0)
Europe 20,091 (5.9) 872 (7.4) 181 (7.1) 1,017 (4.4) 2,233 (6.6)
Asia 19,105 (5.7) 784 (6.7) 188 (7.4) 495 (2.1) 1,213 (3.6)
America/Oceania 3,253 (1.0) 167 (1.4) 47 (1.8) 207 (0.9) 381 (1.1)
Africa 5,297 (1.6) 297 (2.5) 80 (3.1) 70 (0.3) 203 (0.6)
Missing 94 (0) 10 (0.1) 1 (0.0) 1 (0) 6 (0.0)
Year of delivery
1999–2001 37,540 (11.1) 1,346 (11.5) 0 3,097 (13.4) 6,389 (18.9)
2002–2004 39,384 (11.6) 1,250 (10.7) 0 3,268 (14.1) 6,372 (18.9)
2005–2007 43,310 (12.8) 1,198 (10.2) 5 (0.2) 3,368 (14.5) 6,595 (19.5)
2008–2010 53,847 (15.9) 1,544 (13.2) 76 (3.0) 3,872 (16.7) 6,566 (19.4)
2011–2013 66,932 (19.8) 2,533 (21.6) 542 (21.3) 4,259 (18.4) 5,494 (16.3)
2014–2016 97,096 (28.7) 3,856 (32.9) 1,927 (75.6) 5,321 (23.0) 2,344 (6.9)
Highest disposable household income in 3 years preceding delivery
Lowest tertile 44,834 (13.3) 2,674 (22.8) 610 (23.9) 2,555 (11.0) 6,320 (18.7)
Middle tertile 100,738 (29.8) 3,882 (33.1) 758 (29.7) 6,217 (26.8) 11,007 (32.6)
Highest tertile 192,535 (56.9) 5,171 (44.1) 1,181 (46.3) 14,413 (62.2) 16,426 (48.7)
Gestational age estimation method
Ultrasound 309,355 (91.5) 10,828 (92.3) 2,429 (95.3) 20,836 (89.9) 30,148 (89.3
Last menstrual period 15,200 (4.5) 474 (4.0) 45 (1.8) 1,230 (5.3) 2,024 (6.0)
Other4 13,554 (4.0) 425 (3.6) 76 (3.0) 1,119 (4.8) 1,588 (4.7)
Cytology diagnosis
Low grade 9,916 (84.6)
High grade 1,811 (15.4)




Interval from CIN3 diagnosis to delivery (years)
Mean (SD) 4.4 (3.4)
Median (IQR) 3.4 (1.9–6.1)
Interval from delivery to diagnosis of CIN2/CIN3/AIS/cancer (years)
Mean (SD) 4.3 (3.7)
Median (IQR) 3.2 (1.4–6.2)
Data are AU : PleasecheckthattheeditstothelegendforTable1areaccurateandcaptureyourmeaning:presented as number (perc ntage) unl ss otherwise specified. Percen ages are based on thos with available data. Percentages of missing are based on the total
numbers.
1Treatment to achieve pregnancy.
2As reported in antenatal care records. Missing values were interpreted as AU : Ichangedinterpretedaslackinganyintercurrentdiseasetointerpretedasthewomannothavinganyconcurrentdisease:Ifthisisnotcorrect;pleaseedit:the woman not having any concurrent disease, in accordance with how data ar registered in
antenatal care records.
3Highest education level at time of delivery.
4Ultrasound, AU : Pleasecheckthatfootnote4forTable1iscorrect : Accordingtothefootnote; theothercategoryincludesultrasoundandlastmenstrualperiod; eventhoughthesearegivenastheirowncategories:Ifthisisnotcorrect;pleaseedit:last menstrual p riod, and/or estimation of gestational age at delivery ward.
AIS, adenocarcinoma in situ; BMI, body mass index; CIN, cervical intraepithelial neoplasia; IQR, interquartile range; SD, standard deviation.
https://doi.org/10.1371/journal.pmed.1003641.t001
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1,481, 58%) and less frequent in the reference group (n = 163,533, 48%) and subsequent CIN2
+ group (n = 12,730, 38%). Smoking during pregnancy was less common in the reference
group (n = 15,365, 4.5%) than the exposure groups (HPV infection [cytology], n = 1,471,
12.5%; HPV infection [HPV test], n = 177, 6.9%; treated, n = 2,811, 12.1%; subsequent CIN2+,
n = 5,895, 17.5%).
The comparisons presented below for different obstetric outcomes are adjusted logistic
regression analyses; unadjusted analyses are presented in S5–S7 Tables.
Preterm delivery
In the total dataset of 1,787,842 deliveries in 1,044,023 women, 87,727 deliveries (4.9%) were
PTD and 62,951 deliveries were spontaneous PTD (3.5%).
Compared to the reference group (4.6%), the treated group had the highest risk of PTD
(9.1%, adjusted odds ratio [aOR] 1.85, 95% CI 1.76–1.95, p< 0.001), but an increased risk was
also found in the HPV infection (cytology) group (5.9%, aOR 1.21, 95% CI 1.12–1.31, p<
0.001) and the HPV infection (HPV test) group (5.6%, aOR 1.19, 95% CI 1.01–1.42, p = 0.042)
(Table 2; Fig 2A). These results were similar for spontaneous PTD; the treated group had aOR
2.06 (95% CI 1.95–2.17, p< 0.001) and the HPV infection (cytology) group had aOR 1.18
(95% 1.07–1.29, p = 0.001) (Table 2; Fig 2B). The treated group and the HPV infection (cytol-
ogy) group also had increased risk of very early and early PTD (Table 2).
Women in the subsequent CIN2+ group also had a slightly increased risk of PTD (5.1%,
aOR 1.12, 95% CI 1.06–1.18, p< 0.001) and spontaneous PTD (Table 2). However, when it
came to the analyses stratified for interval from delivery to diagnosis, the increase was only sig-
nificant for women diagnosed with CIN2+ within the first 3 years after delivery (Table 3). In
comparison with the other exposure groups (rather than with the reference group), the treated
group exhibited an increased risk of both PTD and spontaneous PTD (Table 4; Fig 2).
Preterm prelabor rupture of membranes
In the study population, 27,687 deliveries started with pPROM (1.5%). Compared to the refer-
ence group (1.5%), the risk of pPROM was increased in the treated group (4.0%, aOR 2.36,
95% CI 2.19–2.54, p< 0.001), the HPV infection (cytology) group (2.0%, aOR 1.22, 95% CI
1.07–1.40, p = 0.004), and the HPV infection (HPV test) group (2.5%, aOR 1.52, 95% CI 1.18–
1.96, p = 0.001) (Table 2; Fig 3). Women in the subsequent CIN2+ group did not have an
increased risk of pPROM compared to the reference group (Table 2), although an increased
risk was found if the women were diagnosed with CIN2+ within the first 3 years after delivery
(Table 3). Compared with the other exposure groups, the treated group had an increased risk
of pPROM (Table 4; Fig 3).
PROM in term pregnancies
Of the 1,700,115 term pregnancies, a total of 111,519 deliveries started with PROM (6.6%).
Women in the treated group had an increased risk of PROM at term compared to the refer-
ence group (8.4% versus 6.8%, aOR 1.11, 95% CI 1.05–1.17, p< 0.001) (Table 2) and compared
to the subsequent CIN2+ group (aOR 1.20, 95% CI 1.11–1.31, p< 0.001) (Table 4). Moreover,
the HPV infection (HPV test) group had an increased risk of PROM compared to the refer-
ence group (aOR 1.24, 95% CI 1.08–1.42, p = 0.002). The associations for the HPV infection
(cytology) group were oriented in the same direction but were not statistically significant
(Table 2).
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Table 2. Obstetric and neonatal outcomes in exposure groups compared to the reference group—adjusted multivariable logistic regression analyses.
Outcome Reference group
(n = 338,109)
HPV infection groups Treated group (n = 23,185) Subsequent CIN2+ group (n
= 33,760)Cytology (n = 11,727) HPV test (n = 2,550)
n (%) n (%) aOR
(95% CI)






p-Value n (%) aOR
(95% CI)
p-Value















































































































































































0.006 7 (0.3) 2.69
(1.25–
5.78)
0.011 47 (0.2) 1.79
(1.30–
2.45)









0.006 6 (0.2) 0.93
(0.41–
2.09)
0.86 74 (0.3) 1.35
(1.05–
1.72)

































































Statistically significant p-values in bold. AU : IaddedStatisticallysignificantp   valuesinbold:tothelegendofalltablesthathadboldedp   values:nalyses adjusted for ye r of delivery, maternal ag , parity, BMI, marital status, country of birth, infant’s sex, smoking, income,
education level, and assisted reproduction.
1Analyses compared to reference group 2007–2016.
2Missing data: reference group, n = 575; HPV infection (cytology) group, n = 24; HPV infection (HPV test) group, n = 3; treated group, n = 47; subsequent CIN2
+ group, n = 71.
aOR, adjusted odds ratio; CI, confidence interval; CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus; pPROM, preterm prelabor rupture of
membranes; PROM, prelabor rupture of membranes; PTD, preterm delivery; SGA, small for gestational age.
https://doi.org/10.1371/journal.pmed.1003641.t002
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SGA and Apgar score
In the study population, 41,323 infants were born SGA (2.3%). Data were missing for 4,028
deliveries (0.2%). There was no difference between the reference group and any of the expo-
sure groups in regard to SGA risk (Table 2).
In the study population, 22,968 babies were born with a 5-minute Apgar score < 7 (1.3%).
The treated group had higher risk of low Apgar score compared to the reference group
(Table 2) and to the subsequent CIN2+ group (Table 4). Furthermore, the HPV infection
(cytology) group had an increased risk of low Apgar score. The association was oriented in the
same direction in the HPV infection (HPV test) group but did not reach significance
(Table 2).
Intrauterine fetal death
There were 5,649 (0.3%) reported cases of intrauterine fetal death in the study population. Com-
pared to the reference group (0.2%), the risk was increased in the HPV infection (cytology)
group (0.4%, aOR 1.55, 95% CI 1.13–2.12, p = 0.006) and in the treated group (0.3%, aOR 1.35,
95% CI 1.05–1.72, p = 0.019), while it was decreased in the subsequent CIN2+ group (0.1%,
aOR 0.71, 95% CI 0.53–0.96, p = 0.026) (Table 2). This decreased risk was significant for the
subsequent CIN2+ subgroup of women who were diagnosed >3 years after delivery (Table 3).
Infectious complications
In the study population, 5,170 (0.3%) deliveries were complicated by chorioamnionitis, 10,832
(0.6%) by intrapartum fever, and 12,923 (0.7%) by neonatal sepsis. The treated group had an
increased risk of chorioamnionitis (0.8%, aOR 2.75, 95% CI 2.33–3.23, p< 0.001), intrapartum
fever (0.9%, aOR 1.24, 95% CI 1.07–1.44, p = 0.003), and neonatal sepsis (1.3%, aOR 1.55, 95%
CI 1.37–1.75, p< 0.001) compared to the reference group (Table 2).
The treated group experienced PTD, pPROM, and infectious complications more fre-
quently than the reference group. For a depiction of the relationship between PTD, pPROM,
and infectious complications in the treated and reference groups, see Fig 4.
Fig 2. Risk of preterm delivery and spontaneous preterm delivery—adjusted logistic regression. Preterm delivery
(2a); spontaneous preterm delivery (2b). Women with HPV infection had an increased risk of preterm delivery and
spontaneous preterm delivery; treatment increased the risk further. aORs are given, with 95% confidence intervals in
parentheses. Analyses adjusted for year of delivery, maternal age, parity, BMI, marital status, country of birth, infant’s
sex, smoking, income, education level, and assisted reproduction. aOR, adjusted odds ratio; CIN, cervical
intraepithelial neoplasia; HPV, human papillomavirus.
https://doi.org/10.1371/journal.pmed.1003641.g002
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After stratification for PTD or not, the increased risk of infectious complications in the
treated versus the reference group was still statistically significant in the PTD group (chor-
ioamnionitis: aOR 3.96, 95% CI 3.13–5.02, p< 0.001; neonatal sepsis: aOR 1.74, 95% CI 1.43–
2.12, p< 0.001), but not in the term delivery group (chorioamnionitis: aOR 1.28, 95% CI
0.98–1.67, p = 0.07; neonatal sepsis: aOR 1.08, 95% CI 0.91–1.29, p = 0.36). There was no clear
increase in infectious complications in the HPV infection groups (Table 2).
Stratifying for pPROM in the PTD cases revealed that the aOR for chorioamnionitis was
higher in the treated group than in the reference group, in both women with pPROM (aOR
3.68, 95% CI 2.70–5.03, p< 0.001) and women without pPROM (aOR 2.19, 95% CI 1.32–3.61,
p = 0.002), but was significantly higher in women with pPROM (p = 0.032). Similarly, AU : Pleasecheckthattheeditstothesentence}Similarly:::}ðmodeledonasimilarsentenceforneonatalmortalitybelowÞcaptureyourmeaning:Ifnot; pleaseprovidecorrectwording:the
increase in risk of neonatal sepsis in the treated group compared to the reference group was
Table 3. Obstetric and neonatal outcomes in the subsequent CIN2+ group compared with the reference group, stratified for interval from delivery to CIN2+ diagno-




Subsequent CIN2+ group Comparison of subsequent CIN2+�3 years and
>3 years after delivery�3 years after delivery
(n = 16,152)
>3 years after delivery1
(n = 17,608)
n (%) n (%) aOR (95%
CI)2






























































































































Statistically significant p-values in bold. Analyses adjusted for year of delivery, maternal age, parity, BMI, marital status, country of birth, infant’s sex, smoking, income,
education level, and assisted reproduction.
1Up to 18 years after delivery.
2Comparison with reference group.
3Missing data: reference group, n = 575; subsequent CIN2+�3 years after delivery, n = 25; subsequent CIN2+ >3 years after delivery, n = 46.
aOR, adjusted odds ratio; CI, confidence interval; CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus; pPROM, preterm prelabor rupture of
membranes; PROM, prelabor rupture of membranes; PTD, preterm delivery; SGA, small for gestational age.
https://doi.org/10.1371/journal.pmed.1003641.t003
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Table 4. Obstetric and neonatal outcomes in the treated group compared to the HPV infection groups and the subsequent CIN2+group—adjusted multivariable
logistic regression analyses. AU : Iaddedanotherlevelofcolumnheadstoaddresstheissuethattherewere3columnsidenticallylabeledTreatedgroup:Pleasecheckthatthesecolumnheadsarecorrect:.
Outcome Treated versus HPV infection (cytology)
comparison
Treated versus HPV infection (HPV test)
comparison





group (n = 11,727)
Treated group
(n = 14,579)
HPV infection (HPV test)
group (n = 2,550)
Treated group,
(n = 18,505)
Subsequent CIN2+ group (n
= 33,760)
n (%) n (%) aOR
(95% CI)
p-Value n (%) n (%) aOR1
(95% CI)
p-Value n (%) n (%) aOR
(95% CI)
p-Value







































0.12 98 (0.7) 7 (0.3) 2.79
(1.23–
6.35)































































































0.89 21 (0.1) 7 (0.3) 0.56
(0.21–
1.45)











0.12 51 (0.3) 6 (0.2) 1.21
(0.49–
3.00)






















































Statistically significant p-values in bold. Analyses adjusted for year of delivery, maternal age, parity, BMI, marital status, country of birth, infant’s sex, smoking, income,
education level, and assisted reproduction.
1Analyses 2007–2016.
2Missing data: treated group, n = 47; HPV infection (cytology) group, n = 24; HPV infection (HPV test) group, n = 3; subsequent CIN2+ group, n = 71.
aOR, adjusted odds ratio; CI, confidence interval; CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus; pPROM, preterm prelabor rupture of
membranes; PROM, prelabor rupture of membranes; PTD, preterm delivery; SGA, small for gestational age.
https://doi.org/10.1371/journal.pmed.1003641.t004
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significantly higher in women with PTD with pPROM (aOR 2.70, 95% CI 1.99–3.68, p<
0.001) than in women with PTD without pPROM (aOR 0.86, 95% CI 0.62–1.20, p = 0.39) (p =
0.015 for the interaction).
Neonatal mortality
There were 2,657 reported cases of neonatal mortality (0.1%). Neonatal mortality was
increased in the treated group (aOR 1.79, 95% CI 1.30–2.45, p< 0.001), as well as in the HPV
infection (cytology) (aOR 1.81, 95% CI 1.19–2.76, p = 0.006) and HPV infection (HPV test)
(aOR 2.69, 95% CI 1.25–5.78, p = 0.011) groups, compared to the reference group (Table 2).
After additional adjustment for PTD, the increased risk of neonatal mortality disappeared
in the treated group, suggesting that the risk increase had been mediated by gestational age.
However, the risk was still increased in the HPV infection groups, i.e., cytology (aOR 1.64,
95% CI 1.07–2.50, p = 0.024) and HPV test (aOR 2.30, 95% CI 1.06–4.99, p = 0.036).
Of those with neonatal mortality, 4.1% in the reference group and 14.9% in the treated
group also contracted chorioamnionitis, and 6.4% in the reference group and 25.5% in the
treated group had infants with neonatal sepsis. For an illustration of the relationship between
neonatal mortality, infectious complications, and PTD, see Fig 5. The increase in risk of
Fig 3. Risk of pPROM—adjusted logistic regression. Women with HPV infection had an increased risk of pPROM;
treatment increased the risk further. aORs are given, with 95% confidence intervals in parentheses. Analyses adjusted
for year of delivery, maternal age, parity, BMI, marital status, country of birth, infant’s sex, smoking, income,
education level, and assisted reproduction. aOR, adjusted odds ratio; CIN, cervical intraepithelial neoplasia; HPV,
human papillomavirus; pPROM, preterm prelabor rupture of membranes.
https://doi.org/10.1371/journal.pmed.1003641.g003
Fig 4. Venn diagram illustrating the relationship between preterm delivery (PTD), preterm prelabor rupture of
membranes (pPROM), and infectious complications in the treated group and the reference group. The treated
group had PTD, pPROM, and infectious complications more frequently. PTD and deliveries after pPROM were more
often complicated by infections in the treated group than in the reference group. The deliveries with infectious
complications were more frequently preterm and complicated by pPROM in the treated group than in the reference
group.
https://doi.org/10.1371/journal.pmed.1003641.g004
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neonatal mortality in the treated group compared to the reference group was significantly
higher in women with infectious complications (chorioamnionitis or neonatal sepsis) (aOR
2.06, 95% CI 1.00–4.24, p = 0.049) than in women without infectious complications (aOR 0.90,
95% CI 0.60–1.34, p = 0.59) (p = 0.015 for the interaction).
Paired analyses
In the paired analyses of 4,680 women with deliveries both before and after treatment, the risk
of PTD (aOR 1.26, 95% CI 1.07–1.49, p = 0.007), spontaneous PTD (aOR 1.23, 95% CI 1.02–
1.49, p = 0.032), and pPROM (aOR 1.72, 95% CI 1.29–2.29, p< 0.001) were increased after
treatment (Table 5). Also, chorioamnionitis and neonatal sepsis had higher odds ratios after
treatment (Table 5).
HPV infection groups
Except for a higher risk of pPROM (aOR 1.43 95% CI 1.03–1.99, p = 0.034) and PROM (aOR
1.26, 95% CI 1.06–1.50, p = 0.008) in the HPV infection (HPV test) group compared to the
HPV infection (cytology) subgroup with no HPV test, no significant differences in outcomes
were found between the HPV infection groups (S8 Table).
Discussion
Main findings
In this population-based study, women with HPV infection shortly before or during preg-
nancy had an increased risk of PTD, spontaneous PTD, pPROM, PROM, and neonatal mortal-
ity. An even higher risk of PTD, spontaneous PTD, and pPROM was found in women with
previous treatment for CIN. Previous treatment was also associated with PROM, neonatal
mortality, and maternal and neonatal infectious complications.
Comparison with previous studies and interpretation
Treatment for CIN and obstetric and neonatal outcomes. The finding that treatment
for CIN is associated with infectious pregnancy complications has not been clearly demon-
strated before, but an increased risk of chorioamnionitis was suggested by a recent meta-
Fig 5. Venn diagram illustrating the relationship between preterm delivery (PTD), infectious complications
(chorioamnionitis/neonatal sepsis), and neonatal mortality in the treated group and the reference group. The
treated group more frequently had PTD, neonatal mortality, and infectious complications. The deliveries resulting in
neonatal mortality more frequently had infectious complications in the treated group than in the reference group.
https://doi.org/10.1371/journal.pmed.1003641.g005
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analysis [10]. To the best of our knowledge, this is the first study to demonstrate that it is not
only the risk of pPROM but also the risk of PROM at term that is increased after treatment for
CIN. Infection is considered to be an important cause of PTD and pPROM [9], while deliveries
after pPROM and PROM also entail increased risk of infectious complications [33]. Our
results could be explained by an increased risk of ascending bacterial infection in women pre-
viously treated for CIN, causing PTD, pPROM, chorioamnionitis, and neonatal sepsis. The
finding of an increased risk of PTD, including pPROM, after treatment is consistent with pre-
vious studies [10]. The risk increase for PTD was similar to results from birth cohort studies in
Finland (1998–2009) and Denmark (1997–2005) [12,14]. The first systematic review that
highlighted the risk of PTD after treatment for CIN was published in 2006 [34]. In our study,
40% of women treated for CIN were treated after 2006. Eighty-nine percent were treated after
1996, indicating that the majority had been treated with the LLETZ technique. The results of
this study thus reflect the risks related to current treatment methods.
HPV infection and obstetric and neonatal outcomes. In this study, women with HPV
infection had increased risk of PTD, pPROM, PROM, and neonatal mortality. Previous studies
have presented conflicting results. A recent population-based study did not confirm an
increased risk of PTD in women positive for high-risk HPV without CIN2+ (aOR 1.11, 95%
CI 0.75–1.66) [20], perhaps due to a lack of power based on the much smaller sample. The risk
AU : Pleasecheckthattheeditstothesentence}Theriskestimates:::}captureyourmeaning:Ifnot; pleaseprovidecorrectwording:estimates in our study (aOR 1.21 for cytology and aOR 1.19 for HPV test) were slightly lower
than that suggested by a recent meta-analysis (aOR 1.50), but within the 95% CI of that study
(1.19–1.88) [22]. HPV has been found in the placenta [19,35], and it has been hypothesized
that HPV might cause placental dysfunction, leading to PTD [18,19]. However, in this study
we found no increase in SGA in the exposed women, suggesting a mechanism other than dys-
functional placenta. In a mouse model, viral infection of the cervix during pregnancy reduced
Table 5. Obstetric and neonatal outcomes in paired analyses of a woman’s last delivery before treatment and first delivery after treatment—conditional logistic
regression analysis (n = 4,680 women).
Outcome Before treatment After treatment Unadjusted analyses Adjusted analyses1
n (%) n (%) OR (95% CI) p-Value aOR (95% CI) p-Value
PTD, <37 weeks 288 (6.2) 355 (7.6) 1.23 (1.06–1.44) 0.008 1.26 (1.07–1.49) 0.007
Early PTD, <34 weeks 72 (1.5) 107 (2.3) 1.49 (1.10–2.00) 0.009 1.61 (1–12–2.33) 0.010
Very early PTD, <28 weeks 11 (0.2) 21 (0.4) 1.91 (0.92–3.96) 0.08 4.50 (0.90–22.45) 0.07
Spontaneous PTD 227 (4.9) 278 (5.9) 1.23 (1.03–1.46) 0.023 1.23 (1.02–1.49) 0.032
pPROM 86 (1.8) 155 (3.3) 1.80 (1.39–2.35) <0.001 1.72 (1.29–2.29) <0.001
PROM in deliveries at � 37 weeks 241 (5.5) 246 (5.7) 1.02 (0.85–1.22) 0.85 1.04 (0.85–1.26) 0.74
SGA2 113 (2.4) 71 (1.5) 0.63 (0.47–0.85) 0.002 0.70 (0.50–0.99) 0.043
Apgar score < 7 at 5 minutes 44 (0.9) 63 (1.3) 1.43 (0.97–2.10) 0.068 1.29 (0.82–2.03) 0.28
Neonatal mortality 6 (0.1) 12 (0.3) 2.00 (0.75–5.33) 0.17 —3 —3
Intrauterine fetal death 9 (0.2) 16 (0.3) 1.78 (0.79–4.02) 0.17 —3 —3
Chorioamnionitis 5 (0.1) 36 (0.8) 7.20 (2.83–18.35) <0.001 14.22 (2.09–96.92) 0.007
Intrapartum fever 24 (0.5) 16 (0.3) 0.67 (0.35–1.26) 0.21 0.83 (0.35–1.94) 0.66
Neonatal sepsis 31 (0.7) 43 (0.9) 1.39 (0.87–2.20) 0.17 1.92 (1.02–3.61) 0.044
Statistically significant p-values in bold.
1Adjusted for BMI, marital status, infant’s sex, smoking, and assisted reproduction.
2Missing data about SGA for 7 women before treatment and 4 women after treatment.
3Too few cases to adjust for in multivariable model.
aOR, adjusted odds ratio; CI, confidence interval; HPV, human papillomavirus; OR, odds ratio; pPROM, preterm prelabor rupture of membranes; PROM, prelabor
rupture of membranes; PTD, preterm delivery; SGA, small for gestational age.
https://doi.org/10.1371/journal.pmed.1003641.t005
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the capacity of the female reproductive tract to prevent ascending bacterial infection [36]. We
did not confirm any association between HPV infection and clinical infectious complications.
However, infections associated with PTD are known to be subclinical to a major extent [37].
It is still unclear whether the HPV infection itself, common confounders, or a genetic pre-
disposition is the causal link behind the association between CIN and PTD. However, our
results suggest that HPV infection might be an important factor. Women developing CIN2
+ after delivery also had a small increased risk of PTD and spontaneous PTD, although it was
not significant in the subgroup of women who were diagnosed more than 3 years after deliv-
ery. This may possibly reflect an ongoing HPV infection during pregnancy and delivery in
women with earlier diagnosis of CIN2+ after birthAU : IchangedearlydiagnosisofCIN2þ toearlierdiagnosisofCIN2þ afterbirth:Ifthisisnotcorrect; pleaseedit:. These findings contr dict the hypothesis of
a common genetic susceptibilityAU : Ichangedcontradictacommongeneticsusceptibilitytocontradictthehypothesisofacommongeneticsusceptibility:Ifthisisnotcorrect; pleaseedit:to both persistent HPV infection and PTD or an association
merely due to confounding.
Strengths and limitations
To the best of our knowledge, this is the largest study to date examining the associations of
HPV infection shortly before or during pregnancy and treatment for CIN with obstetric and
neonatal outcomes. It comprises an entire population, and we believe it compares the largest
number of deliveries before and after treatment for CIN in the same women published so far.
As this is an observational study, causality cannot be established and residual confounding
cannot be ruled out despite thorough adjustments. However, the risk increases for PTD, spon-
taneous PTD, pPROM, and chorioamnionitis found in the treated group were supported by
similar findings in the paired analyses, in which 2 deliveries in the same woman were
compared.
The definition of HPV infection in this study has some potential limitations. To begin with,
relying on positive screening tests may lead to an underestimation of the true incidence and
prevalence as many infections can occur and resolve between testing. A small minority of
HPV tests might have been positive due to exclusive detection of low-risk strains, although the
tests used at Swedish laboratories predominantly specifically detect high-risk HPV. Since HPV
test results only became available in 2007, abnormal cytology was used as a proxy for HPV
infection, as in earlier studies [21,38]. A Swedish study found that 72% of women aged under
40 years with low-grade abnormal cytology were positive for high-risk HPV [39]. Since the
abnormal cytology group in this study also included high-grade abnormality, abnormal cytol-
ogy can be assumed to represent the presence of high-risk HPV to a high degree. Positive HPV
tests/cytology up to 6 months before conception were included in the HPV infection groups,
and some infections might have resolved before pregnancy. However, such misclassification
would have attenuated a true effect. We did not require a negative HPV test in the reference
group, and some women might have had an undetected HPV infection. However, such mis-
classification would have attenuated the associations found for the exposure groups compared
to the reference group. Since no national treatment data are available, CIN3 was used as a
proxy for treatment; all women treated for high-grade lesions are thus not included in the
treated group. For the paired analyses it was not possible to adjust for maternal age and parity,
and these results must thus be interpreted with caution.
Implications and next step for research
The use AU : Pleasecheckthattheeditstothesentence}Theuse:::}captureyourmeaning:Ifnot; pleaseprovidecorrectwording:of HPV te ts in ervical cancer screening has increased during the last decade, which
will facilitate large population-based analysis of the relationship of HPV infection and preg-
nancy outcomes in the near future. Our results support general HPV vaccination programs,
and future studies in vaccinated cohorts will ascertain whether PTD and neonatal mortality
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decrease. Additional experimental studies are also needed to establish the causal pathways
linking HPV infection and treatment for CIN to PTD and other adverse obstetric outcomes.
This may be a key to understanding the biological mechanism leading to PTD. We suggest
that pregnancies after treatment for CIN should be regarded as high-risk pregnancies.
Conclusion
This large population-based study demonstrates that women with HPV infection shortly
before or during pregnancy have an increased risk of PTD, pPROM, PROM, and neonatal
mortality. Treatment for CIN was associated with further increased risk of PTD and pPROM
and was also associated with PROM, neonatal mortality, and an increased risk of maternal and
neonatal infectious complications. These results suggest that pregnancies after treatment for
CIN should be regarded as high-risk pregnancies and counseled accordingly. Furthermore,




S1 Table. Diagnosis codes, according to the International Classification of Diseases–
10th Revision (ICD-10), registered in the Swedish Medical Birth Register, leading to exclu-
sion.
(DOC)
S2 Table. Definition of study groups.
(DOC)
S3 Table. Classification of cervical cytology and histology.
(DOC)
S4 Table. Outcome definition based on diagnosis codes according to the International
Classification of Diseases–10th Revision (ICD-10) in the Swedish Medical Birth Register.
(DOC)
S5 Table. Obstetric and neonatal outcomes in exposure groups compared to the reference
group—univariable logistic regression analyses.
(DOC)
S6 Table. Obstetric and neonatal outcomes in the subsequent CIN2+ group compared with
the reference group, stratified by interval from delivery to CIN2+ diagnosis—univariable
logistic regression analyses.
(DOC)
S7 Table. Obstetric and neonatal outcomes in the treated group compared to the HPV
infection groups and the subsequent CIN2+group—univariable logistic regression analy-
ses.
(DOC)
S8 Table. Outcomes in the HPV infection (cytology) group compared to the HPV infection
(HPV test) group—univariable and multivariable logistic regression analyses, deliveries
2007–2016.
(DOC)
PLOS MEDICINE Treated and untreated HPV infection and preterm delivery and neonatal mortality
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003641 May 10, 2021 19 / 22
Author Contributions
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